Cosmetic, dermatological or cosmeceutical treatment, including progating
Tyrosine derivatives with specific groups enhance melanin production and skin benefits at lower concentrations, addressing stability and solubility issues in existing treatments, and offer UV protection.
Patent Information
- Application Number
- FR2021011341
- Authority / Receiving Office
- FR · FR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2021-10-26
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2041-10-26
AI Technical Summary
Existing cosmetic and cosmeceutical treatments for skin pigmentation, such as those using dihydroxyacetone or tyrosine derivatives like TYR-OL™ and TYR-EXCEL™, face issues with stability, solubility, and effectiveness at lower concentrations, and do not provide adequate UV protection.
The use of tyrosine derivatives with specific hydrocarbon and acyl or sulfonyl groups, such as N-Palmitoyl-O-methyl-L-Tyrosine, which are more soluble and effective at lower concentrations, stimulating melanin production without UV induction, and can be combined with other active ingredients for enhanced benefits.
The tyrosine derivatives effectively increase melanin production, improve skin hydration and elasticity, reduce inflammation, and provide UV protection, while being more stable and soluble at lower concentrations than existing products.
Abstract
Description
Title of the invention: Cosmetic, dermatological or cosmeceutical treatment, in particular progating
[0001] The present invention relates to a cosmetic, dermatological, or cosmeceutical treatment using a tyrosine derivative, in particular a topical pro-pigmenting treatment. It is specifically intended for the treatment of skin and skin appendages in mammals, both human and animal. It is relevant to the cosmetic, dermatological, cosmeceutical, and personal hygiene and care product industries.
[0002] The term "cosmetic or cosmeceutical treatment" means a treatment that treats healthy skin and / or hair, said treatment being intended to improve or enhance their appearance and condition. Such a treatment has no therapeutic purpose.
[0003] By "cosmeceutical treatment" (also commonly called nutraceutical), we mean a non-therapeutic cosmetic treatment by oral route.
[0004] The skin is the first protective barrier between our body and the external environment. It is also the first image we present to others. Throughout history, its appearance has been a subject of concern.
[0005] The cosmetics and cosmeceutical markets are always looking for new active ingredients to improve the general condition of the skin and hair, in particular to give or restore radiance, hydrate, pigment or depigment, protect against external aggressions, such as UV or cold, calm irritations, redness, acne, reduce micro-edema (such as bags under the eyes), reduce dark circles, signs of aging, such as wrinkles, fine lines, restore suppleness and elasticity, treat hair loss, act on adipose tissue, give volume, density, improve texture, etc.
[0006] For example, having a tanned complexion gives a healthy glow and protects the DNA contained in skin cells from UV radiation. However, tanning obtained through exposure to UV radiation, whether naturally from the sun or artificially using a UV lamp, can also damage the skin immediately (sunburn) and in the long term (premature skin aging due to oxidative stress).
[0007] A pro-pigmenting active ingredient stimulates the synthesis of melanin, the natural pigment of the skin, eyes, hair, eyelashes, and nails, thereby intensifying normal skin and hair pigmentation without solar or UV radiation. This type of active ingredient represents an alternative to tanning obtained through UV exposure.
[0008] One example is the use of the well-known molecule dihydroxyacetone (DHA), which, when it comes into contact with amino acids present on the skin, creates a "tanned" effect. However, there are drawbacks to the use of this molecule, such as the unpleasant odor due to the molecules generated by the reaction between DHA and dead skin cells, or the coloration, which consumers find too yellow. Furthermore, it does not provide protection against UV radiation because the coloration is not due to the stimulation of melanin produced in the deep layer of the epidermis by melanocytes, but to a chemical browning of the upper layer of the epidermis.
[0009] The cosmetic use of the amino acid tyrosine is also known to accelerate tanning, but free tyrosine is not readily soluble at the necessary and effective concentrations. Other tanning agents derived from tyrosine were subsequently developed, such as TYR-OL™ and TYR-EXCEL™ offered by Sederma and described respectively in patents FR 2 702 766 and WO03 / 017966, based on oleyl tyrosine, the recommended use of which is between 0.5 and 1.5% oleyl tyrosine.
[0010] Another method used by consumers to achieve a tanned complexion is the use of dietary supplements, often composed of carotenoids and antioxidant vitamins. However, this solution does not provide protection against UV exposure because the resulting skin pigmentation is not due to melanin synthesis.
[0011] The present invention aims to provide new cosmetic, dermatological and cosmeceutical treatments to improve or beautify the general condition of the skin, in particular to artificially pigment it when needed (self-tanning, age spots, pregnancy mask, white spots), the new active ingredients being advantageously able to be used at lower concentrations than existing ones, while exhibiting stability over time and satisfactory solubility.
[0012] To this end, the Applicant proposes the use of at least one compound derived from tyrosine with general formula 1: Or :
[0013] RI is a hydrocarbon chain of 1 to 12 carbon atoms; and • R2 is an acyl or sulfonyl group selected from a biotinoyl group or a group comprising an alkyl, aryl, aralkyl, sugar or alkoxy chain of 1 to 24 carbon atoms, which may be linear, branched or cyclic, saturated or unsaturated, hydroxylated or non-hydroxylated, sulfur-containing or non-sulfur-containing
[0014] for a non-therapeutic cosmetic or nutraceutical treatment to improve or beautify the general condition of the skin and / or its appendages.
[0015] This cosmetic or nutraceutical treatment, particularly suited for preventive or curative use, and containing at least one tyrosine-derived compound according to the invention, is intended to improve or beautify the general condition of the skin and / or its appendages, and is particularly suitable for acting on:
[0016] - skin coloration: for example by increasing melanin production, by reducing skin blemishes, and / or evening out skin tone; and / or
[0017] - hydration: for example by combating skin dryness and / or by protecting or strengthening the skin barrier; and / or
[0018] - the mechanical properties of the skin, for example firmness, elasticity, the suppleness, sagging, wrinkles and fine lines: for example by acting on the synthesis of at least one of the molecules of the dermal extracellular matrix, and / or by limiting the production of free radicals, and / or limiting the glycation of skin proteins; and / or
[0019] - problems related to oily and / or acne-prone skin: for example in reducing the amount of sebum and / or acting on the proliferation of acne-causing bacteria such as C. acnes; and / or
[0020] - adipose tissue: for example by acting on lipogenesis and lipolysis; and / or
[0021] - signs of skin fatigue, such as dull complexion, puffiness and / or dark circles: for example by acting on the production of free radicals, and / or the glycation of skin proteins, and / or cell detoxification; and / or
[0022] - redness and tightness, for example by calming or softening skin altered by cold and / or UV radiation and / or mechanical friction; and / or
[0023] - protection against external aggressions, in particular pollution, the radiation: for example by acting on the skin barrier (its renewal and structure) and / or the microbiome, preventing the appearance of micro-inflammations; and / or
[0024] - the scalp, particularly anti-dandruff: for example by acting on the dryness of the scalp and sebum production;
[0025] - hair, body hair and nails: for example by strengthening their growth and their strength by acting on the pilosebaceous unit, re-epithelialization and / or regeneration; and / or
[0026] - odors: for example by having a deodorizing action.
[0027] The pro-pigmenting cosmetic and / or cosmeceutical treatment according to the invention is particularly suitable for:
[0028] - to stimulate skin pigmentation without UV induction for self-tanning of the skin; and / or
[0029] - to prevent and / or treat loss of skin pigmentation, in particular with a view to to prevent and / or treat white patches or spots on the skin; and / or
[0030] - to prevent and / or treat the loss of pigmentation of hair, body hair, eyelashes and / or eyebrows, particularly with a view to preventing or treating graying and canities; and / or
[0031] - to improve the skin phototype of a person with white and / or sensitive skin particularly with a view to preparing the skin and its appendages for sun exposure; and / or
[0032] - preventing and / or treating uneven skin tone.
[0033] In vitro test results are given later in the description. They show the efficacy of the tyrosine derivative according to the invention in pro-pigmentation, and at lower concentrations than products currently on the market, as well as good solubility. They also show effects, in particular, on the synthesis of extracellular matrix molecules and inflammation.
[0034] The tyrosine derivatives used for the treatment according to the invention may be optically pure, consisting of the L or D isomers, or a mixture thereof. The naturally occurring L isomers are preferred.
[0035] Tyrosine derivatives according to the invention can be manufactured by chemical synthesis, or by biotechnological means (fermentation, synthetic biology, etc.).
[0036] Preferably according to the invention: • the RI group is a hydrocarbon chain of 1 to 6 carbon atoms; preferably, RI is a methyl or ethyl group; preferably, a methyl group; and / or • the R2 group is an acyl or sulfonyl group comprising an alkyl chain of 1 to 24 carbon atoms, which may be linear or branched, saturated or unsaturated, hydroxylated or non-hydroxylated, sulfurized or non-sulfurized; preferably, an acyl group comprising an alkyl chain of 1 to 24 carbon atoms, which may be linear or branched; preferably, an acyl group comprising a saturated linear alkyl chain of 8 to 20 carbon atoms; preferably 14 to 18 carbons.
[0037] The R2 group can thus preferably be chosen from an octanoyl (C8), decanoyl (C10), lauroyl (C12), myristoyl (C14), palmitoyl (C16), stearoyl (C18), biotinoyl, elaiidoyl, oleoyl and lipoyl; preferably still R2 is chosen from a myristoyl (C14), palmitoyl (C16), or a stearoyl (C18); preferably another palmitoyl (Cl6).
[0038] Thus, the particularly preferred tyrosine derivative according to the invention is N-Palmitoyl-O-methyl-L-Tyrosine with the RI group being a methyl, the R2 group being a palmitoyl (Cl6), of general formula 2: 1- H 4
[0039] Preferably according to the invention, the treatment is a topical treatment.
[0040] According to the invention, "topical treatment" or "topical use" means an application intended to act at the site where it is applied: skin, mucous membranes and / or hair.
[0041] The invention also proposes the use of the tyrosine derivative as defined above for the manufacture of a cosmetic or nutraceutical composition intended for treatment to improve or beautify the general condition of the skin and / or its appendages.
[0042] Depending on the physiologically acceptable environment and the concentration of tyrosine derivative, this composition may constitute a concentrated active ingredient intended to be included in a final composition for a consumer, or may directly constitute said final composition.
[0043] By "physiologically acceptable medium" means, according to the present invention, without limitation, an aqueous or hydroalcoholic solution, a water-in-oil emulsion, an oil-in-water emulsion, a microemulsion, an aqueous gel, an anhydrous gel, a serum, a vesicle dispersion, a powder.
[0044] “Physiologically acceptable” means that the compositions are suitable for a Topical or transdermal use, in contact with mucous membranes, nails, scalp, hair, fur, and mammalian, and more specifically human, skin, of compositions that can be ingested or injected into the skin, without risk of toxicity, incompatibility, instability, allergic reaction, and other adverse effects. This "physiologically acceptable medium" forms what is classically called the excipient of the composition.
[0045] The present invention therefore covers a method of topical cosmetic or nutraceutical, non-therapeutic treatment for the beautification or improvement of the appearance and general condition of the skin and / or hair and skin appendages and to treat imperfections, in a subject who needs an effective amount of at least one tyrosine derivative according to the invention or a composition comprising it, in a physiologically acceptable excipient.
[0046] For its use according to the invention, the tyrosine derivatives can be solubilized in a physiologically acceptable lipophilic or hydrophilic matrix, optionally with a solubilizer, depending on the intended dosage form. Preferably, the physiologically acceptable matrix is lipophilic, for example, comprising C8-C10 triglycerides.
[0047] At least one tyrosine derivative according to the invention can be combined with one or more other active ingredients at effective concentrations that can act synergistically or in reinforcement to achieve the desired effects described for the invention, such as the following agents: filtering radiation, in particular UVA, UVB, IR, from blue light, moisturizing, calming, muscle relaxing, slimming, restructuring, firming, plumping, tightening, acting on microcirculation, acting on inflammation, on free radicals, vitamins, anti-wrinkle, etc.
[0048] More specifically, to improve or enhance the overall condition of the skin, the tyrosine derivative according to the invention can be combined, without this list being exhaustive, with one or more active ingredients: - Moisturizing and nourishing, for example Vegesome Moist 24™ (Sederma): active ingredient containing a powder composed of hollow particles of Lycopodium clavatum loaded with an extract of Imperata cylindrica, which gradually moisturizes the epidermis; and / or - Pigmenting agent, for example Silverfree™ (Sederma), an active ingredient containing the Pal-PP peptide which stimulates several steps in the pigmentation process, and / or the Pal-PA peptide and / or, more generally, peptides with pro-pigmenting activity described in the Applicant's patent application WO2014 / 080376, and / or TYR-OL™ and TYR-EXCEL™ offered by Sederma and described respectively in patents FR 2 702 766 and WO03 / 017966, based on oleyl tyrosine, and / or one or more of the noreugenin glycoside derivatives described by UNIVERSITY HAMBURG in patent application WO2017 / 121445, and / or dihydroxyacetone, and / or one or more derivatives of the chromen-4-one family described by MERCK in the patent application WO2007 / 087956; and / or the pyrazolin-4,5-dione-based compounds described by L'Oréal in patent application WO97 / 35842; and / or - Preventing the signs of photoaging, for example Venuceane™ (Sederma): an active ingredient containing a biotechnological extract of Thermus thermophilus, which prevents visible signs of photoaging (spots, wrinkles, dryness, etc.), protects cellular structures from UV damage, and strengthens skin integrity; and / or - Skin tightener, for example Feminage™ (Sederma): active ingredient containing an extract of Engelhardia chrysolepsis which provides elastic and firming properties to the skin; and / or - Anti-pollution, for example Citystem™ (Sederma): active ingredient containing a biotechnological extract of Marrubium vulgare, which makes the skin soft and smooth, refines the skin texture, reduces the visibility of blackheads while leaving the skin radiant and purified.
[0049] Detailed examples are given in the galenic section below.
[0050] A composition according to the invention can be applied to the face, body, décolleté, in any form or vehicle known to those skilled in the art, in particular in the form of a solution, dispersion, emulsion, paste or powder, individually or premixed or be conveyed individually or premixed by vectors such as macrocapsules, microcapsules or nanocapsules, macrospheres, microspheres, or nanospheres, liposomes, oleosomes or chylomicrons, macroparticles, microparticles or nanoparticles, macrosponges, microsponges or nanosponges, microemulsions or nanoemulsions, or adsorbed onto powdered organic polymers, talcs, bentonites, spores or exines and other mineral or organic supports.
[0051] In cosmetics in particular, applications may be proposed, especially in ranges of facial and / or body skin care and makeup-care ranges, particularly eyelashes and eyebrows.
[0052] The composition can also be incorporated on a non-woven or woven material, of natural or synthetic fibers, wool, or on any material intended to come into contact with the skin and which can be used in clothing, in particular tights and socks, shorts, day or night underwear, handkerchiefs, or fabrics, in order to exert its cosmetic effect through this skin / textile contact and allow continuous topical delivery (cosmetotextiles).
[0053] According to the invention, a woven or non-woven material comprising at least one tyrosine derivative is also proposed, for use in a non-therapeutic cosmetic treatment.
[0054] The galenic formulas may be included in ranges of personal care and / or beauty products, including ranges of skin care, cleansing, makeup, makeup removal, sun protection, artificial tanning, pre-shave, shaving, or after-shave, moisturizing, humectant, emollient, conditioning, exfoliating, astringent, depilatory, anti-perspirant or antiperspirant, deodorant, deodorizing, etc.
[0055] The CTFA (International Cosmetic Ingredient Dictionary & Handbook, 10th Ed. 2021, published by the Cosmetic, Toiletry, and Fragrance Association, Inc., Washington, DC) describes a wide variety, without limitation, of cosmetic and pharmaceutical ingredients commonly used in the skincare industry that are suitable for use as additional ingredients in compositions according to the present invention, provided they are physically and chemically compatible with the other ingredients of the composition and especially with the active ingredients of the present invention. Furthermore, the nature of these additional ingredients must not unacceptably alter the benefits of the active ingredients of the invention. These additional ingredients may be synthetic or natural, such as plant extracts, or derived from a biofermentation process.
[0056] Other skin care actives which are particularly useful in combination with the composition according to the invention can be found in the commercial documentation of Sederma and on the website www.sederma.fr, in the commercial documentation of Crodarom and on the website www.croda.fr.
[0057] Other examples include the following commercial active ingredients: betaine, glycerol, Actimoist Bio 2™ (Active Organics), AquaCacteen™ (Mibelle AG Cosmetics), Aquaphyline™ (Silab), AquaregulK™ (Solabia), Carciline™ (Greentech), Codiavelane™ (Biotech Marine), Dermaflux™ (Arch Chemicals, Inc.), Hydra'Flow™ (Sochibo), Hydromoist L™ (Symrise), RenovHyal™ (Soliance), Seamoss™ (Biotech Marine), Argireline™ (the trade name for Lipotec's acetyl hexapeptide-3), spilanthol, or an extract of Acmella oleracea known as Gatuline Expression™, an extract of Boswellia serrata known as Boswellin™, Deepaline PVB™ (Seppic), Syn-AKE™ (Pentapharm), Ameliox™, Bioxilift™ (Silab), PhytoCellTec™Argan (Mibelle), Papilactyl D™ (Silab), Preventhelia™ (Lipotec), or one or more of the following active ingredients sold by Sederma: Subliskin™, Venuceane™, Moist 24™, Vegesome Moist 24™, Essenskin™, Juvinity™, Revidrat™, Resistem™, Chronodyn™, Kombuchka™, Chromocare™,Calmosensine™, Glycokin factor S™, Biobustyl™, Idealift™, Ceramide 2™, Ceramide A2™, Ceramide HO3™, Legance™, Intenslim™, Prodizia™, Beautifeye™, Pacifeel™, Zingerslim™, Meiritage™, Sebuless™, Apiscalp™, Rubistem™, Citystem™, Neonyca™, NG Unsaponifiables of Shea Butter™, Majestem™, Hydronesis™, Poretect™, Amberstem™, Synchrolife™, Sylverfree™, Feminage™, Ameyezing™ or mixtures thereof.
[0058] Among the plant extracts (in the form of conventional extracts or prepared by an in vitro method) that can be used as additional active ingredients, one can mention, in particular, ivy extracts, for example, from common ivy (Hedera helix), Bupleurum chinensis, Bupleurum falcatum, arnica (Arnica montana E.), rosemary (Rosmarinus officinalis N.), willow (Calendula officinalis), sage (Salvia officinalis L.), ginseng (Panax ginseng), ginko biloba, Hypercum perforatum), strawberry (Ruscus aculeatus L.), elm (Filipendula ulmaria L.), orthosiphon (Orthosiphon stamincus Benth.), artichoke (Cynara scolymus), seaweed (Fucus vesiculosus), birch (Betula alba), green thistle, marshmallow (Coronni copila), of India, of bamboo, Centella asiatica, of willow, fucus, willow, piloselle, the extracts of ash, the extracts of cangzhu, the extracts of chrysanthellum indicum, of plants of the genus Armeniacea, Atractylodis platicodon, Sinnomenum, pharbitidis, Fleus pharicodon, C. , C. blumei, C. esquirolii, C. scutellaroides , C. xanthantus and C. barbatus, as an extract of roots of Coleus barbatus, extracts of Ballote, Guioa, Davallia, Terminalia, Barringtonia, Tréma, Antirobia, Cecropia, Argania, Dioscorea or Dioscorea or composite Dioscorea Mexican, extracts of Ammi visnaga, Siegesbeckia, especially Siegesbeckia orientalis, plant extracts of the family Ericaceae, especially extracts of blueberries (Vaccinium angustifollium) of Arctostaphylos uva ursi, Aloe vera, containing stem plants phytosterols), Manjistha (extract of plants of the genus Rubia, especially Rubia cordifolia), Guggal (extract of plants of the genus Commiphora, especially Commiphora mukul), an extract of kola, chamomile, purple clover, Piper methysticum (Kava Kava, Bacoma, Baco). Sederma) and sea whip, Glycyrrhiza glabra, mulberry, melaleuca (tea tree), Larrea divaricata,of Rhabdosia rubescens, of Euglena gracilis, of Fibraurea recisa hirudinea, of Chaparral sorghum, of sunflower, of Enantia chlorantha, of Mitracarpe of the genus Spermacocea, of Buchu barosma, of Lawsonia inermis L^d'Adiantium-Maj. Cylindrical luffa, from Japanese, Mandarin » (Citrus reticulata blanco var. unshiu), of Camélia sinensis, of Imperata cylindrical, of Glaucium flavum, of Cupressus sempervirens, of Polygonatum multiflorum, of Loveyly hemsleya, of Sambucus nigra, of Phaseolus lunatus, of Centaurium, of Macrocystis, of Tupyfferasti, of Tupyfferasti Anemarrhena asphodeloides, Portulaca pilosa, Humulus lupulus, Arabica coffee, Ilex paraguariensis, Globularia cordifolia, Oxydendron arboreum, Albizzia julibrissin, Zingiber zerumbet smith, Astragalus, Atractacelodes macrocephalae, Plantago lanceolata, Leontopodium alpinum (or eldelweiss), Mirabilis jalapa, Apium graveolens, Marrubium vulgare, Buddleja davidii Franch or orchids.
[0059] Compositions according to the present invention can comprise peptides, including, without limitation, the, di-, tri-, tetra-, penta- and hexapeptides and their derivatives. According to a particular embodiment, the concentration of the additional peptide in the composition varies between 1x10 7% and 20%, preferably between 1x10 6% and 10%, preferably between 1x10 5% and 5%, by weight.
[0060] In the context of the present invention, the term "peptide" herein refers to peptides containing 10 amino acids or fewer, their derivatives, isomers, and complexes with other species such as a metal ion (e.g., copper, zinc, manganese, magnesium, and others). The term "peptides" refers both to natural peptides and to (bio)synthetic peptides. It also refers to compositions containing peptides that are found in nature and / or are commercially available.
[0061] Non-limiting examples of dipeptides that can be used in the context of the present invention include Carnosine (beta-AH), YR, VW, NF, DF, KT, KC, CK, KP, KK, TT, PA, PM or PP.
[0062] Non-limiting examples of tripeptides include RKR, HGG, GHK, GGH, GHG, GKH, KPK, KFK, KavaK, K[3AK, KabuK, KacaK, KPK, KMOK, KM02K, PPL, PPR, SPR, QPA, LPA or SPA.
[0063] Non-limiting examples of tetrapeptides are GQPR (SEQ ID NO: 1), RSRK (SEQ ID NO: 2), KTAK (SEQ ID NO: 3), KAYK (SEQ ID NO: 4) or KFYK (SEQ ID NO: 5) or TKPR (SEQ ID NO: 6).
[0064] A non-limiting example of pentapeptide is KTTKS (SEQ ID NO: 7) and of hexapeptides includes GKTTKS (SEQ ID NO: 8) or VGVAPG (SEQ ID NO: 9).
[0065] Other peptides usable within the framework of the present invention may be chosen from, without this list being limiting: lipophilic derivatives of peptides, preferably palmitoyl and myristoyl derivatives, and complexes with the metal ions mentioned above (e.g., copper complex of the tripeptide HGG).
[0066] Preferred dipeptides include, for example, N-Palmitoyl-beta-Ala-His, Pal-KT, Pal-RT (Sederma). Preferred tripeptides include, in particular, the copper derivative of HGG (Lamin™, Sigma), Pal-GHK, lipospondin (N-Elaidoyl-KFK) and its conservative substitution analogues, N-Acetyl-RKR-NH2(Peptide CK +), Pal-KavaK, Pal-K[3AlaK], Pal-KabuK, Pal-KacaK, Pal-KMO2K, N-Biot-GHK (Sederma) and their derivatives.
[0067] We can also mention here the anti-aging tripeptides of general formula X-Pro*-Pro*-Xaa-Y described in application WO2015181688 with Xaa chosen from Leu, Arg, Lys, Ala, Ser, and Asp, at the N-terminal end, X chosen from H, -CO-R1 and -SO2-R* and at the C-terminal end Y chosen from OH, OR1, NH2, NHR1 or NR1 R2, R1 and R2 being, independently of each other, chosen from a group alkyl, aryl, aralkyl, alkylaryl, alkoxy and aryloxy, which may be linear, branched, cyclic, polycyclic, unsaturated, hydroxylated, carbonyl, phosphorylated and / or sulfurized, said group having in its skeleton a heteroatom in particular O, S and / or N, and Pro* corresponding to Proline, an analogue or a derivative thereof; including for example Myr-PPL-OH and Myr-PPR-OH.
[0068] We can also mention here the pro-pigmenting and / or pro-Mec dipeptides and tripeptides of general formula X-(Xaal)n-Pro*-Xaa2-Y described in application WO2014 / 080376, with n=0, 1 or 2, Xaal a hydrophobic amino acid chosen from Ala, Val, Met, Leu, Iso, Phe, Pro, and analogues or derivatives thereof; or a polar amino acid chosen from Ser, Thr, Tyr, Asp, Glu and derivatives and analogues thereof; and when n=2 the two amino acids Xaal may be identical or different; Xaa2 a hydrophobic amino acid chosen from Ala, Val, Met, Leu, Iso, Phe, and analogues or derivatives thereof; a basic amino acid chosen from Arg, Lys, His, and derivatives and analogues thereof; at the N-terminal end of the peptide, X is chosen from H, -CO-R1 and -SO2-R1;at the C-terminal end of the peptide, Y is chosen from OH, OR1, NH2, NHR1 or NR'R2, R' and R2 being, independently of each other, chosen from an alkyl, aryl, aralkyl, alkylaryl, alkoxy and aryloxy group, which may be linear, branched, cyclic, polycyclic, unsaturated, hydroxylated, carbonyl, phosphorylated and / or sulfur-containing, said group being able to possess in its skeleton a heteroatom in particular O, S and / or N; Pro* corresponding to Proline, an analogue or a derivative thereof; including for example the peptides Pal-SPR-OH, Pal-PPR-OH, Pal-QPA-OH, Pal-LPA-OH, Myr-SPA-OH, Pal-PM-OH, Pal-PA-OH and Pal-PP-OH.
[0069] Tetrapeptide derivatives that can be used in the context of the present invention include, but are not limited to, Ela-KTAK (SEQ ID NO: 10), Ela-KAYK (SEQ ID NO: 11), Ela-KFYK (SEQ ID NO: 12) or Pal-GQPR (SEQ ID NO: 13).
[0070] Usable pentapeptide derivatives include, but are not limited to, Pal-KTTKS (SEQ ID NO: 14), N-Pal-Tyr-Gly-Gly-Phe-X (SEQ ID NO: 15) with X being Leu or Pro, N-Pal-His-Leu-Asp-Ile-Ile-X (SEQ ID NO: 16) with X being Trp, Phe, Tyr, Tic, 7-hydroxy-Tic or Tpi, or mixtures thereof.
[0071] An example of a usable hexapeptide derivative includes Pal-GKTTKS (SEQ ID NO: 17).
[0072] Preferred commercially available compositions offered by Sederma:
[0073] - tripeptides or derivatives include, in particular, Biopeptide-CL™, Maxilip™, or Procapil™ containing GHK;
[0074] - tetrapeptides or derivatives include: RIGIN™, Eyeliss™, which contain palmitoyl-GQPR (SEQ ID NO: 13) and an excipient;
[0075] - pentapeptides or derivatives such as Matrixyl™ source of Pal-KTTKS (SEQ ID NO: 14).
[0076] We can also mention:
[0077] - the mixture Pal-GHK and Pal-GQPR (SEQ ID NO: 13) (Matrixyl™ 3000), and
[0078] - the mixture Pal-GHK and Pal-VGVAPG (SEQ ID NO: 18) (Biobustyl™).
[0079] The following commercial peptides may also be mentioned as additional active ingredients: - Vialox™ (INCI name = Pentapeptide-3 (synthetic peptide comprising alanine, arginine, isoleucine, glycine and proline)), Syn-ake™ (|3-Ala-Pro-Dab-NH-Bzl) or Syn-Coll™ (Pal-Lys-Val-Lys-OH) sold by Pentapharm,
[0080] - Argireline™ (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2 (SEQ ID NO: 19) (INCI Name = Acetyl hexapeptide-3), Leuphasyl™ (Tyr-D-Ala-Gly-Phe-Leu (SEQ ID NO: 20)), Aldenine™ (Gly-His-Lys), Trylagen™ (INCI Name = Pseudoalteromonas Ferment Extract, Hydrolyzed Wheat Protein, Hydrolyzed Soy Protein, Tripeptide-10 Citrulline (product of the reaction of citrulline and Tripeptide-10 (synthetic peptide made up of aspartic acid, isoleucine and lysine)), Tripeptide-1), Eyeseryl™ (Ac-[3-Ala-His-Ser-His (SEQ ID NO: 21)), Serilesine™ (Ser-Ile-Lys-Val-Ala-Val (SEQ ID NO: 22)) or Decorinyl™ (INCI Name: Tripeptide-10 Citrulline = product of the reaction of Citrulline and Tripeptide-10 (synthetic peptide made up of aspartic acid, isoleucine and lysine) sold by the company Lipotec,
[0081] - Collaxyl™ (Gly-Pro-Gln-Gly-Pro-Gln (SEQ ID NO: 23)) or Quintescine™ (Cys-Gly) sold by the company Vincience,
[0082] - Cytokinol™LS (casein hydrolysate) sold by Laboratoires Serobiological / Cognis,
[0083] - Kollaren™ (Gly-His-Lys), TIP2000™ (Pal-Val-Tyr-Val) or Meliprene™ (INCI name = Monofluoroheptapeptide-1: product of the reaction of acetic acid and a synthetic peptide containing arginine, glycine, glutamic acid, histidine, norleucine, p-fluorophenylalanine and tryptophan) sold by the European Institute of Cell Biology,
[0084] - Neutrazen™ (Pal-His-D-Phe-Arg-NH2) sold by the company Innovations, or
[0085] - BONT-L-Peptide™ (INCI name = Palmitoyl Hexapeptide-19: product of the reaction of palmitic acid and Hexapeptide-19 (synthetic peptide composed of asparagine, aspartic acid, lysine, and methionine), Timp-Peptide™ (INCI name = Acetyl Hexapeptide-20: product obtained by acetylation of Hexapeptide-20 (synthetic peptide composed of alanine, glycine, lysine, valine, and proline) or ECM Moduline™ (INCI name = Palmitoyl Tripeptide-28: product of the reaction of palmitic acid palmitic and Tripeptide-28 (synthetic peptide made up of arginine, lysine and phenylalanine) sold by the company Infinitec Activos.
[0086] It is also conceivable to combine the invention with one or more cyclic peptides in particular those extracted from linseed oil described in the Applicant's patent application FRI850845.
[0087] Tyrosine derivatives according to the invention or the composition containing them can also be combined with at least one of the compounds selected from vitamin B3 compounds, compounds such as niacinamide or tocopherol, retinoid compounds such as retinol, hexamidine, a-lipoic acid, resveratrol or DHEA, hyaluronic acid, peptides, including N-acetyl-Tyr-Arg-O-hexadecyl, Pal-VGVAPG (SEQ ID NO: 18), Pal-KTTKS (SEQ ID NO: 14), Pal-GHK, Pal-KMO2K, Pal-GQPR (SEQ ID NO: 13) and Pal-K(P)HG, which are classic active ingredients used in topical cosmetic or dermo-pharmaceutical compositions.
[0088] Tyrosine derivatives or the composition according to the invention can be applied locally to the targeted areas.
[0089] The "effective" amount of tyrosine derivatives according to the invention, that is, its dosage, depends on the intended use of the composition. It depends on various factors, such as age, the patient's condition, and the severity of the disorder. An effective amount means a non-toxic quantity sufficient to achieve the desired effect.
[0090] In a composition containing at least one tyrosine derivative according to the invention, to be present in an effective quantity, it is generally found in proportions between 0.000001% and 15% by weight of the total composition, preferably between 0.00001% and 10%, depending on the intended use of the composition and the desired effect. Preferably, the effective quantity is between 0.0001% and 0.01% by weight of the total composition, a quantity well below current market standards.
[0091] All percentages and ratios used in this application are by weight of the total composition and all measurements are taken at 25°C, unless otherwise specified.
[0092] For example, for a cosmetic facial treatment, the European Cosmetics Directive has set a standard application quantity of a cream of 2.72 mg / cm2 / day / person and for a body lotion of 0.5 mg / cm2 / day / person.
[0093] According to other features, the cosmetic treatment process according to the invention can be associated with one or more other skin treatment processes, such as light therapy, heat therapy or aromatherapy treatments.
[0094] According to the invention, it is possible to propose multi-compartment devices or kits intended for the implementation of the process described above, and which could include, by way of example, and without limitation, in a first compartment a composition containing the tyrosine derivative of the invention in an excipient, and in a second compartment a second tyrosine derivative according to the invention in an additional excipient and / or active ingredient, the compositions contained in said first and second compartments being herein considered as a combination composition for simultaneous, separate or spread-out use in particular in one of the treatments defined above. DETAILED DESCRIPTION
[0095] The present invention will be better understood in the light of the following description of an example of embodiment and in vitro tests.
[0096] 1) Preparation of compositions for the implementation of the present invention
[0097] a) Example s of obtaining a preferred tyrosine derivative for the production of work of the invention: N-Palmitoyl-O-methyl-L-Tyrosine
[0098] The tyrosine derivative is prepared by chemical synthesis. The starting material is commercially available L-methylated tyrosine (H-Tyr(Me)-OH), which is suspended in a suitable solvent (N-Butylpyrolidone), then heated and palmitoyl chloride added. The resulting solid is filtered and then dissolved in a mixture of solvents to crystallize. The crystallized product is finally washed with a suitable solvent and dried.
[0099] b) Example of preparing a cosmetic composition according to the invention forming an active ingredient comprising the tyrosine derivative
[0100] The tyrosine derivative is lipophilic. It is solubilized, for example at 2000 ppm, in a C8Ci0 triglyceride matrix. 2) In vitro tests
[0101] They were conducted on the tyrosine derivative N-Palmitoyl-O-methyl-L-Tyrosine, the preparation of which is described above. The in vitro tests below were carried out on normal human melanocytes (NHM), mouse B16 cells, keratinocytes, or fibroblasts, depending on the test. The tyrosine derivative according to the invention was tested in solution in a solvent (acidified dimethyl sulfoxide (DMSO)) at concentrations recommended for in vitro use. a) Melanin stimulation without UV induction protocol
[0102] MNH were cultured and placed in contact with the product according to the invention for 10 days. Following this contact, the mats were ground up and the melanin was extracted from the cells. The amount of melanin was evaluated by spectrophotometry, using from a previously established standard range, and compared to the control. A protein assay using the bicinchoninic acid (BCA) method was used to estimate the number of cells and to homogenize the data obtained.
[0103] In parallel, mouse B16 cells were cultured and then exposed to the product according to the invention for 2 days. The number of cells did not vary significantly, as the product was neither toxic nor a proliferative activator. Results
[0104] [Table 1]
[0105] Effect of the tyrosine derivative according to the invention on melanin production by MHN (n=4): Melanin (pg / mL / 10⁶ cells) Variation (%); significance Control 269+ / -19 Reference 5.5 ppm of the tyrosine derivative according to invention 1 404+ / -42 +50%; p<0.01 11 ppm of the tyrosine derivative according to invention 501+ / -41 +86%; p<0.01
[0106] The results show that melanin production by MNH is greatly increased by the derivative according to the invention in the absence of UV induction.
[0107] [Table 2]
[0108] Effect of the tyrosine derivative according to the invention on melanin production and tyrosinase activity by mouse B16 cells (n=4): Melanin (pg / 10⁶ cells) Variation (%); significance Tyrosinase (U / 1000pg protein) Variation (%); significance Control 136 + / - 2.8 Reference 2.5 + / - 0 Reference 5.5 ppm of the tyrosine derivative according to the invention 171.1 + / - 2.3 +26%; p<0.01 2.8 + / - 0 +9.7%; p<0.01 11 ppm of the tyrosine derivative according to the invention 220.7 + / - 8.7 +62%; p<0.01 3.1 + / - 0 +20.5%; p<0.01
[0109] Tyrosinase is the first enzyme in the melanogenesis pathway; it converts tyrosine into DOPA-quinone. The results show that melanin production and tyrosinase activity by mouse B16 cells are significantly increased by the derivative according to the invention in the absence of UV induction.
[0110] These two tests demonstrate the pro-pigmenting activity of a tyrosine derivative according to the invention, and the cosmetic or cosmeceutical use that can result therefrom.
[0111] b) Comparison of 1' o leyl tyrosine vs. the tyrosine derivative according to the invention Protocol
[0112] The tests were carried out on MNH, the protocol is identical to that above. Results
[0113] At 16ppm, the tyrosine derivative according to the invention induces an increase in the pigmentation of these cells of 52% (p<0.01 vs. control) whereas 16ppm of oleyl tyrosine induces a variation of 9% (dns vs. control).
[0114] With approximately 3 times more oleyl tyrosine applied to the cells, +35% pigmentation of MNH is achieved (p<0.01 vs . control).
[0115] At equivalent concentrations, the tyrosine derivative according to the invention is therefore more active than oleyl tyrosine. Approximately three times more oleyl tyrosine is required to achieve an effect equivalent to that of the tyrosine derivative according to the invention.
[0116] c) Increased phagocytosis of keratinocytes Protocol
[0117] Normal human keratinocytes (NHKs) were seeded and, once they reached 50% sub-confluence, received the tyrosine derivative according to the invention, or its solvent, at different concentrations for 24 hours. At the end of this period, the cells received fluorescent microbeads mimicking melanosomes for 3 hours. The cells were then rinsed to remove excess microbeads, and the mats were visualized under a fluorescence microscope to quantify phagocytosis. The cell concentration was estimated using the Hoescht method. Results
[0118] [Table 3]
[0119] Effect of the tyrosine derivative according to the invention on the phagocytosis of KHN (n=4): Phagocytosis (pbilles: (Total Area / 1000)) Variation (%); meaning activity Control 3864+ / -582 Reference 5.5 ppm of the tyrosine derivative according to the invention 6599+ / -1115 +71% ;p<0.01 11 ppm of the tyrosine derivative according to the invention 9910+ / -1161 +129% ;p<0.01
[0120] The results show that phagocytosis of keratinocytes is greatly increased thanks to the derivative according to the invention.
[0121] This shows in particular that more melanin is transferred to keratinocytes, which further increases skin colouring and better protects cells from solar radiation.
[0122] d) S synthesis of the extracellular matrix of keratinocytes Protocol
[0123] HaCaT keratinocytes were seeded and, once subconfluence was reached, received the tyrosine derivative according to the invention, or its solvent, at different concentrations for 3 days. At the end of this period, the media were collected for hyaluronic acid and laminin assays using ELIS A methods. The cell concentration was estimated using the Hoescht method. Results
[0124] [Table 4]
[0125] Effect of the tyrosine derivative according to the invention on the production of hyaluronic acid (n=4): Hyaluronic acid (ng / 10⁶ cells) Variation (%); significance Control 298+ / -21 Reference 1.375 ppm of the tyrosine derivative according to invention 402+ / -35 +35%; p<0.01 2.75 ppm of the tyrosine derivative according to invention 391+ / -25 +31%; p<0.01
[0126] The results show that hyaluronic acid in keratinocytes is greatly increased by the derivative according to the invention.
[0127] This shows in particular that the hydration and elasticity of the skin are better with the use of the tyrosine derivative according to the invention.
[0128] [Table 5]
[0129] Effect of the tyrosine derivative according to the invention on the production of laminins (n=4): Laminin (ng / 10⁶ cells) Variation (%); denotes activity Control 66+ / -5 Reference 2.75 ppm of the invention tyrosine derivative 88+ / -3 +33%; p<0.01 5.5 ppm of the tyrosine derivative according to invention 111+ / -9 +69%; p<0.01
[0130] Laminins are molecules found in the epidermis that play a role in strengthening the dermis / epidermis junction. They are contained in the basal layer and contribute to anchoring cell surfaces to the basal lamina. They thus provide the keratinocyte of the basal lamina with better anchorage and help maintain the elasticity of the epidermis.
[0131] The results show that laminins in keratinocytes are greatly increased by the derivative according to the invention. e) Anti-inflammatory activity protocol
[0132] Keratinocytes were seeded and, once subconfluence was reached, received the tyrosine derivative according to the invention, or its solvent, at different concentrations. After 24 hours, the cells were rinsed and then exposed to UVB, and subsequently the cells were again exposed to the media containing the tyrosine derivative according to the invention at different concentrations for 24 hours. Other cells were not exposed. The culture media were assayed for PGE2, IL6, and IL8 using ELIS A methods. The number of cells was estimated using the Hoescht method.
[0133] In parallel, normal human fibroblasts (NHFs) were seeded and, once subconfluence was reached, received the tyrosine derivative according to the invention, or its solvent, at different concentrations. After 24 hours, the cells were rinsed and exposed to UVB, and then the cells were again given media containing the tyrosine derivative according to the invention at different concentrations for 24 hours. Other cases were not exposed. The culture media were assayed for PGE2 using ELIS A methods. The number of cells was estimated using the Hoescht method. Results
[0134] [Table 6]
[0135] Effect of the tyrosine derivative according to the invention on PGE2 contained in keratinocytes (n=3): PGE2 without irradiation (ng / 10⁶ cells) Variation (%); significance PGE2 with UVB irradiation (ng / 10⁶ cells) Variation (%); significance Control 129+ / -5 Reference 268+ / -20 Reference 5.5 ppm of the tyrosine derivative according to the invention ion 51+ / -5 -60%; p<0.01 101+ / -7 -62%; p<0.01 11 ppm of the tyrosine derivative according to the invention ion 54+ / -5 -58%; p<0.01 72+ / -3 -73%; p<0.01
[0136] The results show that the production of PGE2 in keratinocytes, induced by UVB irradiation or not, is greatly reduced thanks to the derivative according to the invention.
[0137] [Table 7]
[0138] Effect of the tyrosine derivative according to the invention on PGE2 contained in fibroblasts (n=3): PGE2 without irradiation (ng / 10⁶ cells) Variation (%); significance PGE2 with UVB irradiation (ng / 10⁶ cells) Variation (%); significance Control 11073+ / -1110 Reference 9067+ / -549 Reference 5.5 ppm of the tyrosine derivative according to the invention ion 7420+ / -422 -32%; p<0.01 7332+ / -478 -19%; dns * 11 ppm of the tyrosine derivative according to the invention ion 6470+ / -311 -41%; p<0.01 6117+ / -735 -33%; p<0.01
[0139] *dns: non-significant data
[0140] The results show that the production of PGE2 in fibroblasts, induced by UVB irradiation or not, is greatly reduced thanks to the derivative according to the invention.
[0141] [Table 8]
[0142] Effect of the tyrosine derivative according to the invention on IL6 and IL8 contained in keratinocytes (n=2): IL-6 with UVB irradiation (ng / 10⁶ cells) Variation (%); significance IL-8 with UVB irradiation (ng / 10⁶ cells) Variation (%); significance Control 7.4 + / - 0.7 Reference 1555 + / - 142 Reference 5.5 ppm of the tyrosine derivative according to the invention 4.3 + / - 0.7 -42%; p < 0.01 880 + / - 142 -43%; p < 0.01 11 ppm of the tyrosine derivative according to the invention ion 0.7+ / -0 -90%; p<0.01 853+ / -115 -45%; p<0.01
[0143] The results show that the production of IL6 and IL8 in keratinocytes, induced by UVB irradiation, is greatly reduced thanks to the derivative according to the invention.
[0144] These results demonstrate a preventive anti-inflammatory effect of the tyrosine derivative according to the invention. The cells are better protected. From a cosmetic point of view, the treatment according to the invention helps prevent discomfort, such as tightness, and unsightly imperfections, such as micro-redness of the skin, for example due to external aggressions such as pollution, radiation, or cold. 3) Galenic
[0145] Examples of galenic formulation are given below containing at least one compound derived from tyrosine according to the invention as the active molecule, in particular as formulated in the active ingredient described in point 1) b) above.
[0146] Furthermore, this formulation may also contain other additional cosmetic active ingredients, which may, where appropriate, support and / or complement the activity of the active ingredient according to the invention. These ingredients may be of any category depending on their function(s), the area of application (body, face, neck, bust, hands, etc.), the desired end effect, and the target consumer, for example, anti-aging, moisturizing, firming, anti-redness, anti-stretch mark, etc.
[0147] To have an effect, the recommended concentration of use of the tyrosine derivative according to the invention is between 0.002% and 0.01% to obtain an effective concentration. By comparison, the recommended use of oleyl tyrosine is between 0.5% and 1.5%.
[0148] Example 1: Self-tanning cream
[0149] [Tables9] Raw materials % Name INCI Phase A Span 60 ™ (Croda) Cyclopentasiloxane (and) Cyclohexas iloxane Crodamol OP™ (Croda) Arlacel 170 ™ (Croda) Ethylhexyl Methoxycinnamate Ethylhexyl Dimethyl PABA 3.00 2.00 3.00 3.00 1.00 1.00 Sorbitan Stearate Cyclopentasiloxane (and) Cyclohexasiloxane Ethylhexyl Palmitate Glyceryl Stearate (and) PEG-100 Stearate Ethylhexyl Methoxycinnamate Ethylhexyl Dimethyl PABA Phase B: Carbomer qs. 0.40 (Water, Carbomer) Phase C: Glycerin, Preservatives 5.00 (Glycerin) Phase D: Cosmetic active ingredient comprising a tyrosine derivative according to invention 2.00 Phase E: Osmocide™ 2 (Sederma) 4.00 (Glycerin (and) Water (and) PEG-8 (and) Caprylyl Glycol (and) Sodium Polyacrylate Phase F: Potassium Sorbate 0.10 Phase G: 30% Sodium Hydroxide 6.00 0.60 (Water, Sodium Hydroxide) Protocol
[0150] Heat A. Weigh B and let it rest. Melt C, then add B. Heat B+C, then add A, then D, then E, then F and finally G. Homogenize.
[0151] Example 2: Spray oil for evening out skin tone
[0152] [TableauxlO] Raw materials % INCI Name Phase A Crodamol™ GTCC (Croda) Crodamol™ OS (Croda) Ethylhexyl Methoxycinnamate Ethylhexyl Dimethyl PABA Tocopherol acetate qsp 20.00 2.00 2.00 0.20 Caprylic / Capric Triglyceride Ethylhexyl Stearate Ethylhexyl Methoxycinnamate Ethylhexyl Dimethyl PABA Tocopherol acetate Phase B Cosmetic active ingredient comprising a tyrosine derivative according to invention 2.00 Protocol
[0153] Homogenize A, then add B, then add C. Homogenize.
[0154] Example 3: Complexion brightening gel
[0155] [Tableauxll] Raw Materials % INCI Name Phase A h2o qs Water Carbomer 0.20 Carbomer Phase B PEG 400 Preservatives 5.00 qs PEG 400 Phase C Dimethicone Acrylates / C10-30 Alkyl Acrylate Cross Polymer 4.00 0.20 Dimethicone Acrylates / C 10-30 Alkyl Acrylate Cross Polymer Phase D Tween 20™ (Croda) Cosmetic active ingredient comprising a tyrosine derivative according to invention 1.00 2.00 Polysorbate 20 Phase E Potassium Sorbate 0.10 Potassium Sorbate Phase F Osmocide™ 2 (Sederma) 4.00 Glycerin (and) Water (and) PEG-8 (and) Caprylyl Glycol (and) Sodium Polyacrylate Phase G h2o Sodium hydroxide 5.00 0.60 Water Sodium hydroxide Protocol
[0156] Heat phase B. Mix A+B and C+D separately. Add (C+D) to (A+B), then E, then F. Let stand and add G, then H.
[0157] Examples of ingredients that can be added to these formulations (marketed by SEDERMA):
[0158] VENU CE ANE™: active ingredient containing a biotechnological extract of Thermus thermophilus, which prevents visible signs of photoaging (spots, wrinkles, dryness...), protects cellular structures from damage caused by UV rays and strengthens skin integrity; AQUALANCE™: osmoprotective moisturizing active ingredient; CALMOSENSINE™: calming active ingredient.
Claims
Claims
1. Use of at least one compound derived from tyrosine of general formula 1: Or: - RI is a hydrocarbon chain of 1 to 12 carbon atoms; - R2 is an acyl or sulfonyl group chosen from a biotinoyl group or a group comprising an alkyl, aryl, aralkyl, sugar or alkoxy chain of 1 to 24 carbon atoms, which may be linear, branched or cyclic, saturated or unsaturated, hydroxylated or non-hydroxylated, sulfurized or non-sulfurized for a non-therapeutic cosmetic or nutraceutical treatment to improve or beautify the general condition of the skin and / or its appendages.
2. Use of at least one compound derived from tyrosine of general formula 1: Or: - RI is a hydrocarbon chain of 1 to 12 carbon atoms; - R2 is an acyl or sulfonyl group chosen from a biotinoyl group or a group comprising an alkyl, aryl, aralkyl, sugar or alkoxy chain of 1 to 24 carbon atoms, which may be linear, branched or cyclic, saturated or unsaturated, hydroxylated or non-hydroxylated, sulfurated or non-sulfurated in a physiologically acceptable medium, for the manufacture of a composition intended for a cosmetic or nutraceutical treatment to improve the general condition of the skin and / or its appendages.
3. Use according to claim 1 or 2, characterized in that R2 is chosen from octanoyl (C8), decanoyl (C10), lauroyl (C12), myristoyl (C14), pahnitoyl (C16), stearoyl (C18), biotinoyl, elaidoyl, oleoyl and lipoyl.
4. Use according to one of the preceding claims, characterized in that R2 is a pahnitoyl (Cl6).
5. Use according to one of the preceding claims, characterized in that the tyrosine of the derivative according to the invention is the L isomer.
6. Use according to one of the preceding claims, characterized in that RI is a hydrocarbon chain of 1 to 6 carbon atoms.
7. Use according to the preceding claim, characterized in that RI is a methyl or ethyl group.
8. Use according to one of the preceding claims, characterized in that the tyrosine derivative is N-Palmitoyl-O-methyl-L-Tyrosine, in which RI is a methyl group, R2 is a palmitoyl group and comprising the L isomer of tyrosine.
9. Use according to one of the preceding claims, characterized in that the treatment is topical.
10. Use according to one of the preceding claims, for a preventive or curative treatment intended to improve or beautify the general condition of the skin and / or its appendages, in particular adapted to act on - the coloring of the skin; and / or - hydration; and / or - the mechanical properties of the skin; and / or - problems linked to oily and / or acne-prone skin; and / or - adipose tissue; and / or - signs of skin fatigue; and / or - protection against external aggressions; and / or - the scalp, - hair, body hair and nails; and / or - odors.
11. Use according to one of the preceding claims, characterized in that the treatment is a pro-pigmenting treatment.
12. Use according to claim 10, characterized in that the treatment is chosen from a self-tanning treatment making it possible to stimulate the coloring of the skin without UV induction, and / or a treatment to prevent and / or treat the loss of pigmentation of the skin and its appendages (hair, eyelashes, eyebrows or hair), and / or a treatment to improve the skin phototype of a person with white and / or sensitive skin and / or a self-tanning or tanning accelerating treatment, and / or a treatment to prevent and / or treat the lack of unification of the complexion.
13. Use according to claim 10 or 11, characterized in that the pro-pigmenting treatment is a treatment for white spots on the skin and / or canities.
14. Use according to claim 10, 11 or 12, characterized in that the pro-pigmenting treatment is a treatment for preparing the skin and its appendages for exposure to the sun.
15. Use according to one of the preceding claims, characterized in that the cosmetic treatment is suitable for maintaining and / or improving the elasticity and suppleness of the skin.
